<DOC>
	<DOCNO>NCT02918084</DOCNO>
	<brief_summary>Breast cancer common form cancer among woman . For patient candidated adjuvant chemotherapy endocrine therapy optimal time clearly define yet .</brief_summary>
	<brief_title>CONcurrent vs SEqueNTial Adjuvant Treatments Early Breast Cancer</brief_title>
	<detailed_description>Breast cancer common form cancer among woman North America , Europe Latin America . Because nearly 80 % breast cancer endocrine-responsive tumor , majority patient candidate adjuvant chemotherapy ( CT ) also candidate endocrine therapy ( ET ) . The optimal timing ( i.e . concomitant vs sequential administration ) integration two treatment clearly define yet . In patient hormone receptor positive early stage breast cancer candidate adjuvant chemotherapy endocrine therapy , optimal time integration two treatment modality clearly define yet .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Women histological diagnosis invasive breast cancer completely remove surgery , T , N. Postmenopausal status define least one follow condition : 1 . Aged ≥ 60 2 . Aged 4559 satisfy one follow criterion : amenorrhea ≥12 month intact uterus ; amenorrhea &lt; 12 month folliclestimulating hormone ( FSH ) within postmenopausal range , include : pt hysterectomy pt receive hormone replacement therapy ( HRT ) pt chemotherapyinduced amenorrhea 3. bilateral oophorectomy age &gt; 18 year . Primary tumor positive Estrogen Receptors ( ER ) and/or Progesteron receptor ( PgR ) ( ≥1 % tumor cell positive immunohistochemistry ≥ 10 fmol/mg cytosol protein ligand bind assay ) . Patients prescribed 5 year endocrine therapy aromatase inhibitor ( AI ) Indication adjuvant chemotherapy Patients HER2 positive tumor eligible provide prescribed trastuzumab accord registered schedule . Signed informed consent . HRT currently assume month randomization Recurrent metastatic disease HER2 positive tumor treatment trastuzumab consider appropriate/feasible Concurrent illness contraindicate adjuvant endocrine treatment and/or chemotherapy Patients receive Tamoxifen part breast cancer prevention trial Previous history invasive breast cancer invasive malignancy within previous 10 year , squamous basal cell carcinoma skin carcinoma situ cervix , adequately cone biopsied Concomitant severe disease would place patient unusual risk Concurrent treatment experimental drug Patients treat systemic investigational drug within past 30 day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>sequential administration chemiotherapy</keyword>
	<keyword>early breast cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>adjuvant</keyword>
	<keyword>post menopausal</keyword>
</DOC>